Team:Washington/Gram Negative/Design

From 2010.igem.org

(Difference between revisions)
(Using Type VI Secretion as an Antibacterial Agent)
(Heterologous Expression of T6SS)
Line 29: Line 29:
Our overall goal is to clone the Type 6 secretion system and the Tse2/Tsi2 toxin/antitoxin system from ''Pseudomonas aeruginosa'' into ''E. coli'' to make a strain of ''E. coli'' that could be used to kill off gram negative pathogens present in the human gut. Ideally, this system would be regulated in such a way that the strain of ''E. coli'' would only be able to kill gram negative bacteria when a gram negative pathogen is present. This strain could (ideally) be introduced into the gut either as a preventive measure or as a treatment after a known infection. Ideally, the probiotic would only kill of gram negative bacteria in the area of infection.  
Our overall goal is to clone the Type 6 secretion system and the Tse2/Tsi2 toxin/antitoxin system from ''Pseudomonas aeruginosa'' into ''E. coli'' to make a strain of ''E. coli'' that could be used to kill off gram negative pathogens present in the human gut. Ideally, this system would be regulated in such a way that the strain of ''E. coli'' would only be able to kill gram negative bacteria when a gram negative pathogen is present. This strain could (ideally) be introduced into the gut either as a preventive measure or as a treatment after a known infection. Ideally, the probiotic would only kill of gram negative bacteria in the area of infection.  
==Cool Picture goes here==
==Cool Picture goes here==
-
==Heterologous Expression of T6SS==
+
==Designing the T6SS for a ''E. coli'' probiotic==
 +
'''Justin and or Laura, please write this section'''
In order to create a probiotic application for this system, we first attempt to express it heterologously in non-pathogenic ''E. Coli''.  Starting from a Fosmid containing our T6SS, we are using [http://web.ncifcrf.gov/research/brb/recombineeringInformation.aspx Recombineering] to replace the strict native regulation with robust T7 promoters to create strong expression of the T6SS.   
In order to create a probiotic application for this system, we first attempt to express it heterologously in non-pathogenic ''E. Coli''.  Starting from a Fosmid containing our T6SS, we are using [http://web.ncifcrf.gov/research/brb/recombineeringInformation.aspx Recombineering] to replace the strict native regulation with robust T7 promoters to create strong expression of the T6SS.   

Revision as of 04:16, 29 September 2010

Overall Objective:Using Type VI Secretion as an Antibacterial Agent

Our overall goal is to clone the Type 6 secretion system and the Tse2/Tsi2 toxin/antitoxin system from Pseudomonas aeruginosa into E. coli to make a strain of E. coli that could be used to kill off gram negative pathogens present in the human gut. Ideally, this system would be regulated in such a way that the strain of E. coli would only be able to kill gram negative bacteria when a gram negative pathogen is present. This strain could (ideally) be introduced into the gut either as a preventive measure or as a treatment after a known infection. Ideally, the probiotic would only kill of gram negative bacteria in the area of infection.

Cool Picture goes here

Designing the T6SS for a E. coli probiotic

Justin and or Laura, please write this section In order to create a probiotic application for this system, we first attempt to express it heterologously in non-pathogenic E. Coli. Starting from a Fosmid containing our T6SS, we are using [http://web.ncifcrf.gov/research/brb/recombineeringInformation.aspx Recombineering] to replace the strict native regulation with robust T7 promoters to create strong expression of the T6SS.

All the essential genes for our T6SS are contained within two putative operons, encoded in opposite directions. The native promoters for both operons are found in the same intergenic region, between fha1 and tssA1. Therefore, we can easily replace the promoter regions for both operons in one step.

Toxin/Antitoxin Inducible Circuit

One of the major proteins exported into prokaryotic cells by the T6SS of is the toxin Tse2 ( type six excreted 2). Tse2 is toxic to a wide range of gram-negative bacteria. In P. aeruginosa, Tse2 is coexpressed on the same operon with Tsi2. Tsi2 binds to Tse2 until Tse2 is excreted by the T6SS, and acts as an antitoxin. Inducing transcription of the Tse2/Tsi2 operon initiated the ability of the T6SS to cause cell death ( puncturing of the cellular membrane with the T6SS does not cause cell death). By inducing Tse2 production only when a pathogen is present, T6SS engineered bacteria would be a more finely targeted antibacterial agent than traditional chemical antibiotics.


Overview of the Gram(-) Therapeutic       Building the Gram(-) Therapeutic